Anemia is associated with decreased survival time in dogs with lymphoma

Journal of Veterinary Internal Medicine

Volumn 23, Issue 1, 2009, Pages 116-122

  Miller, A G ^a   Morley, P S ^a   Rao, S ^a   Avery, A C ^a   Lana, S E ^a   Olver, C S ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Anemia of inflammatory disease; Cancer related anemia; Canine; Lymphosarcoma; osteosarcoma; PCV

Indexed keywords

ANEMIA; ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; DOG; DOG DISEASE; FEMALE; LYMPHOMA; MALE; OSTEOSARCOMA; RETROSPECTIVE STUDY; SURVIVAL;

ANEMIA; ANIMALS; DOG DISEASES; DOGS; FEMALE; LYMPHOMA; MALE; OSTEOSARCOMA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

ANIMALIA; CANIS FAMILIARIS;

EID: 61349096669     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.0210.x     Document Type: Article

References (31)

1. Blohmer J, Dunst J, Harrison L, et al. Cancer-related anemia: Biological findings, clinical implications and impact on quality of life. Oncology 2005;68(Suppl):12-21.
2. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence and treatment of anemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
3. Caro J, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer. Cancer 2001;91:2214-2221.
4. Wayner T, Harrus S. Anemia of inflammatory disease. In: Feldman BF, Zinkl J, Jain N. eds. Schalm's Veterinary Hematology. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:205-208.
5. Thrall MA. Veterinary Hematology and Clinical Chemistry. Baltimore, MD: Lippincott Williams & Wilkins; 2004:91-92.
6. Feldman BF, Kaneko JJ. The anemia of inflammatory disease in the dog. I. The nature of the problem. Vet Res Commun 1981;4:237-252.
7. Feldman BF, Kaneko JJ, Farver TB. Anemia of inflammatory disease in the dog: Clinical characterization. Am J Vet Res 1981;42:1109-1113.
8. Feldman BF, Keen CL, Kaneko JJ, Farver TB. Anemia of inflammatory disease in the dog: Measurement of hepatic superoxide dismutase, hepatic nonheme iron, copper, zinc cerulo plasmin and serum iron, copper and zinc. Am J Vet Res 1981;42:1114-1117.
9. Feldman BF, Kaneko JJ, Farver TB. Anemia of inflammatory disease in the dog: Availability of storage iron in inflammatory disease. Am J Vet Res 1981;42:586-589.
10. Feldman BF, Kaneko JJ, Farver TB. Anemia of inflammatory disease in the dog: Ferrokinetics of adjuvant-induced anemia. Am J Vet Res 1981;42:583-585.
11. Ganz T. Hepcidin and its role in regulating systemic iron metabolism. Hematol Am Soc Hematol Educ Program 2006; 29-35.
12. Madewell BR, Feldman BF. Characterization ofanemias associated with neoplasia in small animals. J Am Vet Med Assoc 1980;176:419-425.
13. Callan MB, Oakley DA, Shofer FS, Giger U. Canine red blood cell transfusion practice. J Am Anim Hosp Assoc 1996;32: 303-311.
14. Hohenhaus AE. Transfusion issues in the cancer patient. Clin Tech Small Anim Pract 2003;18:135-138.
15. Abbo AH, Lucroy MD. Assessment of anemia as an independent predictor of response to chemotherapy and survival in dogs with lymphoma, 96 cases (1993-2006). J Am Vet Med Assoc 2007;231:1836-1842.
16. Lana SE, Jackson TL, Burnett RC, et al. Utility ofpolymerase chain reaction for analysis of antigen receptor rearrangement in staging and predicting prognosis in dogs with lymphoma. J Vet Intern Med 2006;20:329-334.
17. Baskin CR, Couto CG, Wittum TE. Factors influencing first remission and survival in 145 dogs with lymphoma: A retrospective study. J Am Anim Hosp Assoc 2000;36:404-409.
18. Carter RF, Harris CK, Withrow SJ, et al. Chemotherapy of canine lymphoma with histopathological correlation: Doxorubicin alone compared to COP as first treatment regimen. J Am Anim Hosp Assoc 1987;23:587-596.
19. Moore AS, Dernell WS, Ogilvie GK, et al. Doxorubicin and BAY12-9566 for the treatment of osteosarcoma in dogs, a randomized, double blind, placebo-controlled study. J Vet Intern Med 2007; 21:783-790.
20. Birgegård G, Aapro M, Bokemeyer C, et al. Cancer-related anemia: Pathogenesis, prevalence and treatment. Oncology 2005;68(Suppl):3-11.
21. Honda K, Ishiko O, Tatsuta I, et al. Anemia-inducing substance from plasma ofpatients with advanced malignant neoplasms. Cancer Res 1995;55:3623-3628.
22. Ishiko I, Sugawa T, Tatsuta I, et al. Anemia-inducing substance (AIS) in advanced cancer: Inhibitory effect of AIS on the function oferythrocytes and immunocompetent cells. Jpn J Cancer Res 1987;78:596-606.
23. Oh-Uti K, Inoue S, Minato S. Purification of and anemia-inducing factor from human placenta and its application to diagnosis of malignant neoplasms. Cancer Res 1980;40: 1686-1690.
24. Mallery KF, Freeman LM, Harpster NK, Rush JE. Factors contributing to the decision for euthanasia of dogs with congestive heart failure. J Am Vet Med Assoc 1999;214:1201-1204.
25. Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoietin alfa on hematologic parameters and quality oflife in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
26. Stasi R, Amadori S, Littlewood TJ, et al. Management of cancer-related anemia with erythropoietic agents: Doubts, certainties and concerns. Oncologist 2005;10:539-554.
27. Bohlius J, Langensiepen S, Shwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients: Results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;97:489-498.
28. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin-An updated overview. Nature 2006;3:152-164.
29. Winter SC, Shah KA, Campo L, et al. Relation of erythro- poietin and erythropoietin receptor expression to hypoxia and anemia in head and neck squamous cell carcinoma. Clin Cancer Res 2005;11:7614-7620.
30. Khuri FR. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 2007;24: 2445-2448.
31. Cowgill LD, James KM, Levy JK, et al. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure. J Am Vet Med Assoc 1998;212: 521-528.